https://www.selleckchem.com/pr....oducts/PD-0332991.ht
These findings may help in minimizing the risk of off-target effects of gene editing. Interleukin 6 (IL6) is increased in patients with progressive prostate cancer and induces its transdifferentiation to neuroendocrine prostate cancer. Neuroendocrine prostate cancer has become one of the greatest challenges in treating castration-resistant disease and is linked to poor prognosis. It is necessary to understand better the cellular events associated with IL6-mediated neuroendocrine differentiation to prevent it and identify potential ne
Like
Comment
Share
